Literature DB >> 33553197

SNRNP200 Mutations Cause Autosomal Dominant Retinitis Pigmentosa.

Tao Zhang1,2, Jingshan Bai3,4, Xinyi Zhang1,2, Xiaowei Zheng1,2, Nan Lu5, Zhongyin Liang6, Ling Lin2,7, Yongsong Chen2,8.   

Abstract

The small nuclear ribonucleoprotein 200 kDa (SNRNP200) gene plays a key role in the maturation of pre-message RNA (pre-mRNA) splicing with the indication for the etiology of retinitis pigmentosa (RP). Gene recognition can facilitate the diagnosis of these patients for better clinical management, treatment and counseling. This study aimed to outline the causative mutation in a Chinese family and the pathogenic mechanism of this SNRNP200 mutation in RP. Eighteen individuals from the affected family underwent a complete ophthalmic examination. Whole exome sequencing (WES) was conducted to identify the pathogenic variant in the proband, which was then confirmed by Sanger sequencing. Expression of the SNRNP200 transcript in zebrafish was identified via whole mount in situ hybridization. Morpholino oligonucleotide (MO) and SNRNP200 wild and mutant mRNA were injected into zebrafish embryos followed by analyses of the systemic changes and retinal phenotypes using immunofluorescence. Heterozygous SNRNP200c.C6088T (p.Arg2030Cys) mutation was ascertained in two members of this family: the proband and his father (II-2). Overexpression of SNRNP200Arg2030Cys, but not SNRNP200WT caused systemic deformities in the wild-type zebrafish embryos with the retina primarily injured, and significantly increased death rates in the morphant embryos, in which the orthologous zebrafish SNRNP200 gene was blocked. In conclusion, this study reports a novel heterozygous SNRNP200c.C6088T mutation, which is evidenced to cause RP via a dominant-negative effect.
Copyright © 2021 Zhang, Bai, Zhang, Zheng, Lu, Liang, Lin and Chen.

Entities:  

Keywords:  SNRNP200; morpholino oligonucleotide; mutation; retinitis pigmentosa; whole exome sequencing

Year:  2021        PMID: 33553197      PMCID: PMC7859630          DOI: 10.3389/fmed.2020.588991

Source DB:  PubMed          Journal:  Front Med (Lausanne)        ISSN: 2296-858X


  25 in total

1.  Mutations in ASCC3L1 on 2q11.2 are associated with autosomal dominant retinitis pigmentosa in a Chinese family.

Authors:  Ningdong Li; Han Mei; Ian M MacDonald; XiaoDong Jiao; J Fielding Hejtmancik
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-08-26       Impact factor: 4.799

Review 2.  Retinitis Pigmentosa: Progress and Perspective.

Authors:  Qingjiong Zhang
Journal:  Asia Pac J Ophthalmol (Phila)       Date:  2016 Jul-Aug

3.  Mutations in a protein target of the Pim-1 kinase associated with the RP9 form of autosomal dominant retinitis pigmentosa.

Authors:  T Jeffrey Keen; Matthew M Hims; Arthur B McKie; Anthony T Moore; Rob M Doran; David A Mackey; David C Mansfield; Robert F Mueller; Shomi S Bhattacharya; Alan C Bird; Alexander F Markham; Chris F Inglehearn
Journal:  Eur J Hum Genet       Date:  2002-04       Impact factor: 4.246

4.  Mutations in the pre-mRNA splicing factor gene PRPC8 in autosomal dominant retinitis pigmentosa (RP13).

Authors:  A B McKie; J C McHale; T J Keen; E E Tarttelin; R Goliath; J J van Lith-Verhoeven; J Greenberg; R S Ramesar; C B Hoyng; F P Cremers; D A Mackey; S S Bhattacharya; A C Bird; A F Markham; C F Inglehearn
Journal:  Hum Mol Genet       Date:  2001-07-15       Impact factor: 6.150

Review 5.  Brr2p RNA helicase with a split personality: insights into structure and function.

Authors:  Daniela Hahn; Jean D Beggs
Journal:  Biochem Soc Trans       Date:  2010-08       Impact factor: 5.407

6.  A human homolog of yeast pre-mRNA splicing gene, PRP31, underlies autosomal dominant retinitis pigmentosa on chromosome 19q13.4 (RP11).

Authors:  E N Vithana; L Abu-Safieh; M J Allen; A Carey; M Papaioannou; C Chakarova; M Al-Maghtheh; N D Ebenezer; C Willis; A T Moore; A C Bird; D M Hunt; S S Bhattacharya
Journal:  Mol Cell       Date:  2001-08       Impact factor: 17.970

7.  Mutations in HPRP3, a third member of pre-mRNA splicing factor genes, implicated in autosomal dominant retinitis pigmentosa.

Authors:  Christina F Chakarova; Matthew M Hims; Hanno Bolz; Leen Abu-Safieh; Reshma J Patel; Myrto G Papaioannou; Chris F Inglehearn; T Jeffrey Keen; Catherine Willis; Anthony T Moore; Thomas Rosenberg; Andrew R Webster; Alan C Bird; Andreas Gal; David Hunt; Eranga N Vithana; Shomi S Bhattacharya
Journal:  Hum Mol Genet       Date:  2002-01-01       Impact factor: 6.150

8.  Autosomal-dominant retinitis pigmentosa caused by a mutation in SNRNP200, a gene required for unwinding of U4/U6 snRNAs.

Authors:  Chen Zhao; Deepti L Bellur; Shasha Lu; Feng Zhao; Michael A Grassi; Sara J Bowne; Lori S Sullivan; Stephen P Daiger; Li Jia Chen; Chi Pui Pang; Kanxing Zhao; Jonathan P Staley; Catharina Larsson
Journal:  Am J Hum Genet       Date:  2009-10-29       Impact factor: 11.025

9.  Mutational screening of splicing factor genes in cases with autosomal dominant retinitis pigmentosa.

Authors:  Paola Benaglio; Patricia Fernandez San Jose; Almudena Avila-Fernandez; Giulia Ascari; Shyana Harper; Gaël Manes; Carmen Ayuso; Christian Hamel; Eliot L Berson; Carlo Rivolta
Journal:  Mol Vis       Date:  2014-06-18       Impact factor: 2.367

10.  SMN deficiency causes tissue-specific perturbations in the repertoire of snRNAs and widespread defects in splicing.

Authors:  Zhenxi Zhang; Francesco Lotti; Kimberly Dittmar; Ihab Younis; Lili Wan; Mumtaz Kasim; Gideon Dreyfuss
Journal:  Cell       Date:  2008-05-16       Impact factor: 41.582

View more
  2 in total

1.  Comprehensive analysis of spliceosome genes and their mutants across 27 cancer types in 9070 patients: clinically relevant outcomes in the context of 3P medicine.

Authors:  Zhen Ye; Aiying Bing; Shulian Zhao; Shuying Yi; Xianquan Zhan
Journal:  EPMA J       Date:  2022-05-10       Impact factor: 8.836

Review 2.  Genetic dissection of non-syndromic retinitis pigmentosa.

Authors:  Aarti Bhardwaj; Anshu Yadav; Manoj Yadav; Mukesh Tanwar
Journal:  Indian J Ophthalmol       Date:  2022-07       Impact factor: 2.969

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.